Grimes & Company, Inc. Mersana Therapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.31 Billion
- Q2 2024
A detailed history of Grimes & Company, Inc. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 14,998 shares of MRSN stock, worth $31,645. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,998
Previous 15,347
2.27%
Holding current value
$31,645
Previous $68,000
55.88%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding MRSN
# of Institutions
124Shares Held
114MCall Options Held
73.5KPut Options Held
46.4K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$40.9 Million1.38% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$23.9 Million2.5% of portfolio
-
Nextech Invest Ag9.53MShares$20.1 Million3.61% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$18.3 Million3.56% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$17.7 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $205M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...